4//SEC Filing
Pershing Edward 4
Accession 0001493152-25-018381
CIK 0000315545other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 9:41 AM ET
Size
9.0 KB
Accession
0001493152-25-018381
Insider Transaction Report
Form 4
Pershing Edward
DirectorCEO
Transactions
- Exercise/Conversion
Series D-1 Convertible Preferred Stock
2025-10-16+18,880→ 2,503,379 totalFrom: 2025-10-16→ Common Stock (188,800 underlying) - Exercise/Conversion
8% Unsecured Convertible Promissory Note
2025-10-16Exercise: $2.86From: 2024-10-16Exp: 2025-10-16→ Series D-1 Convertible Preferred Stock (18,880 underlying)
Footnotes (4)
- [F1]Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- [F2]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
- [F3]The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing.
- [F4]On October 16, 2025, the 2024 Note was converted into 18,880 shares of Series D-1 Preferred Stock.
Documents
Issuer
PROVECTUS BIOPHARMACEUTICALS, INC.
CIK 0000315545
Entity typeother
Related Parties
1- filerCIK 0001689739
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 9:41 AM ET
- Size
- 9.0 KB